Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Scheduling of anticancer drugs: timing may be everything.

Literature DB >> 23032365

Scheduling of anticancer drugs: timing may be everything.

Astrid A M Van der Veldt¹, Adriaan A Lammertsma, Egbert F Smit.

Abstract

Many cancer patients are treated with a combination of anticancer drugs. Here, we discuss the importance of drug scheduling and the need for studies that investigate the optimal timing of the various anticancer drugs. Positron emission tomography (PET) using radiolabeled anticancer drugs could be an important tool for those studies.

Entities: Disease Species

Mesh：

Substances：

Year: 2012 PMID： 23032365 PMCID： PMC3552916 DOI： 10.4161/cc.22187

Source DB: PubMed Journal: Cell Cycle ISSN： 1551-4005 Impact factor: 4.534

48 in total

Review 1. Angiogenesis as a therapeutic target.

Authors: Napoleone Ferrara; Robert S Kerbel
Journal: Nature Date: 2005-12-15 Impact factor: 49.962

2. Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245

3. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245

4. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors: Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal: N Engl J Med Date: 2006-12-14 Impact factor: 91.245

Review 5. Individualized treatment planning in oncology: role of PET and radiolabelled anticancer drugs in predicting tumour resistance.

Authors: Astrid A M van der Veldt; Gert Luurtsema; Mark Lubberink; Adriaan A Lammertsma; N Harry Hendrikse
Journal: Curr Pharm Des Date: 2008 Impact factor: 3.116

6. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

Authors: Kathy Miller; Molin Wang; Julie Gralow; Maura Dickler; Melody Cobleigh; Edith A Perez; Tamara Shenkier; David Cella; Nancy E Davidson
Journal: N Engl J Med Date: 2007-12-27 Impact factor: 91.245

7. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil.

Authors: M Moehler; A Dimitrakopoulou-Strauss; F Gutzler; U Raeth; L G Strauss; W Stremmel
Journal: Cancer Date: 1998-07-15 Impact factor: 6.860

8. Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma.

Authors: A Dimitrakopoulou-Strauss; L G Strauss; P Schlag; P Hohenberger; M Möhler; F Oberdorfer; G van Kaick
Journal: J Nucl Med Date: 1998-07 Impact factor: 10.057

9. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer.

Authors: Robert Gray; Suman Bhattacharya; Christopher Bowden; Kathy Miller; Robert L Comis
Journal: J Clin Oncol Date: 2009-08-31 Impact factor: 44.544

10. Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients.

Authors: Nishi Gupta; Azeem Saleem; Barbara Kötz; Safiye Osman; Eric O Aboagye; Robert Phillips; Clare Vernon; Harpreet Wasan; Terry Jones; Peter J Hoskin; Patricia M Price
Journal: Clin Cancer Res Date: 2006-05-15 Impact factor: 12.531

6 in total

1. A Microfluidic Perfusion Platform for In Vitro Analysis of Drug Pharmacokinetic-Pharmacodynamic (PK-PD) Relationships.

Authors: Yadir A Guerrero; Diti Desai; Connor Sullivan; Erick Kindt; Mary E Spilker; Tristan S Maurer; Deepak E Solomon; Derek W Bartlett
Journal: AAPS J Date: 2020-03-02 Impact factor: 4.009

Review 2. Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors: Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal: World J Clin Oncol Date: 2014-12-10

3. Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment.

Authors: Jennifer Hazel Elizabeth Baker; Alastair Hugh Kyle; Stefan Alexander Reinsberg; Firas Moosvi; Haley Margaret Patrick; Jordan Cran; Katayoun Saatchi; Urs Häfeli; Andrew Ivor Minchinton
Journal: Clin Exp Metastasis Date: 2018-09-08 Impact factor: 5.150

4. Positron Emission Tomography as a Method for Measuring Drug Delivery to Tumors in vivo: The Example of [(11)C]docetaxel.

Authors: Astrid A M van der Veldt; Egbert F Smit; Adriaan A Lammertsma
Journal: Front Oncol Date: 2013-08-13 Impact factor: 6.244

Review 5. Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents.

Authors: Marta Cesca; Francesca Bizzaro; Massimo Zucchetti; Raffaella Giavazzi
Journal: Front Oncol Date: 2013-10-01 Impact factor: 6.244

Review 6. How Signaling Molecules Regulate Tumor Microenvironment: Parallels to Wound Repair.

Authors: Peter Gál; Lenka Varinská; Lenka Fáber; Štepán Novák; Pavol Szabo; Petra Mitrengová; Andrej Mirossay; Pavel Mučaji; Karel Smetana
Journal: Molecules Date: 2017-10-26 Impact factor: 4.411

6 in total